Check out our latest publication!
“Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case”
Don’t miss this incredible research article by Tatham et al. which has been published recently in Microbiology Spectrum.
This study explores the effect of Ronapreve on viral replication in mice infected with either the Delta or Omicron variants, using a reliable murine SARS-Cov-2 infection model. The results showed that Ronapreve was effective against the Delta variant, reducing virus levels in the lungs and nasal turbinate, and blocking brain infection in mice. However, its ineffectiveness against Omicron was also confirmed.
Read the full article here: Long COVID EU Project Publication
Tatham L, Kipar A, Sharp J, Kijak E, Herriott J, Neary M, Box H, Gallardo Toledo E, Valentijn A, Cox H, Pertinez H, Curley P, Arshad U, Rajoli RKR, Rannard S, Stewart JP, Owen A.2024.Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case. Microbiol Spectr12:e03916-23.https://doi.org/10.1128/spectrum.03916-23
